RT team
Japan’s Takeda Pharmaceutical has granted Indian drugmakers Sun Pharmaceutical and Cipla the rights to commercialize its gastrointestinal medication, Vonoprazan, in India. Known under the brand name ‘Voltapraz,’ this drug effectively blocks a crucial step in stomach acid production, as detailed by Sun Pharma this Friday. Cipla confirmed their partnership agreement a day earlier, on Thursday.
Both Sun Pharma and Cipla have received non-exclusive patent licensing from Takeda, allowing them to market Vonoprazan across India, where gastroesophageal reflux disease (GERD) impacts between 5% and 28.5% of the population.
This licensing deal follows a similar agreement earlier this month between Takeda and another Indian pharmaceutical firm, Torrent Pharmaceuticals, to also commercialize Vonoprazan in the region.
Following the announcement, Sun Pharmaceutical’s stock saw a rise of 0.7%, while Cipla experienced a 1% increase in their shares, reflecting positive market reception to this strategic expansion in their gastrointestinal treatment portfolios.
